Hemodialysis Management of Anemia in Chronic Kidney Disease
Pathophysiology of CKD Anemia
- Erythropoietin (EPO) deficiency (peritubular fibroblast loss)
- Iron restriction (hepcidin-mediated blockade of absorption/mobilization)
- Uremic toxin suppression of erythropoiesis
- Blood loss (dialysis circuit, lab draws, GI angiodysplasia)
- Folate/B12 deficiency (dialysis loss, poor intake)
How Hemodialysis Addresses Each
- EPO Stimulation: Uremic clearance improves residual renal EPO; but most still need ESA therapy (epoetin, darbepoetin).
- Iron Repletion: IV iron (sucrose, gluconate, ferric derisomaltose) during dialysis bypasses hepcidin blockade. Target TSAT >20%, ferritin >100 ng/mL.
- Folate/B12: Dialytic loss replaced via IV/oral supplementation.
- Toxin Removal: High-flux/HDF enhances middle-molecule clearance (β2-microglobulin, indoxyl sulfate).
- Blood Conservation: Closed-circuit rinse-back, minimized lab draws, heparin titration.
Monitoring
Monthly Hb, quarterly iron studies, ESA dose adjustment per KDIGO guidelines (target Hb 10–11.5 g/dL). Avoid Hb >13 g/dL (stroke/thrombosis risk).
Kidney Disease - Related Articles
- Kidney Stone Recurrence: Risks, Causes & Prevention Strategies
- Kidney Disease: Symptoms, Causes, and Treatment Options
- Kidney Functions: Filtration, Blood Pressure, Fluid Balance, and Hormone Production
- Kidney Stones: Causes, Pain Relief & Natural Remedies
- Tamsulosin for Kidney Stones: Off-Label Use, Effectiveness, and Precautions
- Coriander Juice for Kidney Stones: What Science Actually Says
- Pediatric Renal Insufficiency: Treatment Options & Management
